Schmallenberg virus (SBV) is an RNA virus of the Bunyaviridae family, genus Orthobunyavirus that infects wild and livestock species of ruminants. While inactivated and attenuated vaccines have been shown to prevent SBV infection, little is known about their mode of immunity; specifically, which components of the virus are responsible for inducing immunological responses in the host.
Introduction
Schmallenberg virus (SBV) is a member of the Bunyaviridae family (genus Orthobunyaviridae). Discovered in Germany in 2011 Gibbens, 2012; Hoffmann et al., 2012) , SBV has spread throughout the European continent, spanning from Ireland to Turkey (Yilmaz et al., 2014) . Initially characterized in domesticated sheep, goat and cattle, further epidemiological studies have linked SBV to wild ruminants such as deer, mouflon (i.e. wild sheep) and bison (Larska et al., 2013a (Larska et al., , 2014 Wernike et al., 2015b) . In affected herds, SBV infection has been associated with diarrhea, fever and decreased milk production Wernike et al., 2013b; Peperkamp et al., 2015; LievaartPeterson et al., 2015) . Although symptoms are generally mild and short-lived in adult ruminants, SBV infection has been linked to widespread abortions and developmental malformations in newborn domestic ruminant livestock (Bayrou et al., 2014) .
SBV is an arthropod-borne pathogen that has been shown to be transmitted by biting midges (i.e. Culicoides) (Balenghien et al., 2014; Larska et al., 2013b Larska et al., , 2013c . Structural information on the whole virion is lacking and only the tridimensional crystal structure of the nucleoprotein is known (Dong et al., 2013; Ariza et al., 2013) . Phylogenetic studies have shown the L, M and S-segments of the SBV genome to be most similar to viruses of the Simbu serogroup of orthobunyaviruses, with viruses of the species Sathuperi virus being the closest relatives .
Currently, inactivated vaccines against SBV are available for use in ruminant animals, and have been shown to be effective in inducing neutralizing antibodies and completely inhibiting viral replication upon experimental viral challenge (Hechinger et al., 2014; Wernike et al., 2013c) . While effective, the cost-benefit ratio of the inactivated SBV vaccine may prevent its widespread use, possibly due to the fact that SBV outbreaks appear to be endemic, e.g. in Germany (Wernike et al., 2015c) . Therefore, a more practical approach to SBV vaccination may involve the development of lower-cost subunit vaccines or DNA vaccines (Babiuk et al., 2014; Kutzler and Weiner, 2008) . However, the efficacy of such as strategy depends on the ability of individual recombinant viral proteins to induce a potent immune response.
Previously, the use of DNA vaccination against components of Rift Valley fever virus (RVFV) with particular emphasis on studying the protective role of glycoproteins (encoded by the M segment), as well as the nucleoprotein was successfully evaluated (Lagerqvist et al., 2009; Boshra et al., 2011a) . Using interferon a/b knockout mice (IFNAR À/À ), it was demonstrated that the glycoproteinencoding segment of RVFV could confer complete protection against viral challenge (Lagerqvist et al., 2009; Lorenzo et al., 2010) ; and that nucleoprotein, when expressed as a fusion protein with ubiquitin, can also confer near-complete protection against RVFV infection (Boshra et al., 2011b) . In the case of SBV, monoclonal antibodies generated in mice inoculated with whole virus demonstrated a high degree of antigenicity against the N-terminal portion of glycoprotein C (G C ; aa 468e702 of the M-segment), as well as the nucleoprotein (Wernike et al., 2015a) , with the former being associated with neutralizing activity (Roman-Sosa et al., 2016) . However, whether or not these antigenic sites are sufficiently immunogenic to induce a complete protective immune response in vivo is not known. Over the past two decades, IFNAR À/À mice have been used as animal models for the study of bunyaviral infection and immunity (Lorenzo et al., 2010; Boshra et al., 2011b; Hefti et al., 1999; Pavlovic et al., 2000; Schuh et al., 1999; Proenca-Modena et al., 2015; Oestereich et al., 2014; Zivcec et al., 2013) . Recently, IFNAR À/À mice were also shown to be susceptible to SBV infection Ponsart et al., 2014; Sailleau et al., 2013) . Although, unlike with RVFV, clinical signs were not as evident following infection with virulent strains of the virus. While IFNAR À/À mice infected with RVFV resulted in complete mortality, IFNAR À/À infected with virulent SBV displayed primarily decreased weight loss, ataxia, apathy and limited mortality (Kraatz et al., 2015) . This model has already been used to validate deletion mutants of SBV for their potential use as attenuated strains for vaccination (i.e. mutants lacking NSm and/or NSs) (Kraatz et al., 2015) . Here, we report on the use of DNA vaccination, encoding for different components of SBV. These include: a putative ectodomain of glycoprotein N (G N ) (aa 23e181), and two putative ectodomain segments of glycoprotein C (aa 468e1403), G C -ecto1 (aa 678e947) and G C -ecto2 (aa 866e1323) as well as ubiquitinated and nonubiquitinated forms of the nucleoprotein (N).
We show that, when expressed separately, cDNAs encoding for the G C eecto1 as well as the nucleoprotein N can render mice asymptomatic following SBV challenge. These results demonstrate that individual components of SBV used here are sufficient to induce protective immunity; and serve as a basis for the creation of subunit vaccines against Schmallenberg virus infection in ruminants.
Materials and methods

Virus and mice
The BH80/11-4 strain of SBV was amplified once in cultured BHK cells in order to obtain sufficient titers for subsequent challenge studies. The mice used were Sv/129 IFN a/b À/À (B & K Universal Ltd, UK). All experiments were performed in the BSL3 facilities of INIA-CISA (Madrid), adhering to institutional and ethical guidelines for animal care and experimentation. Approval for the containment, vaccination, viral challenge and euthanasia were obtained prior to all in vivo experiments being performed. Throughout all steps of experimentation, the mice were monitored by staff veterinarians, and all animals that showed significant signs of morbidity were sacrificed by cervical dislocation.
Construction of DNA vaccines
Five DNA-vaccines were designed based on different components of Schmallenberg virus (Fig. 1A) , using pCMV-based expression vectors (pOPIN vector suite; Oxford Protein Production Facility UK). The vectors either lacked a secretory signal (pOPINE for N and ubiquitinated-N), or possessed a secretory signal (pOPING for G Necto, G C -ecto1, G C -ecto2). An empty vector was used as a negative control and all constructs possessed a carboxy-terminal histidine tag for in vitro confirmation of expression (Fig. 1B) . All viral genes were synthesized (Genscript, USA), based on the Schmallenberg virus isolate Bovine Schmallenberg virus BH80/Germany/2011. PCR amplification steps were performed using Fusion HF DNA polymerase (New England Biolabs, USA).
The nucleoprotein alone as well as the ubiquitinated construct, was expressed as the complete 233-amino acid protein (Genbank accession number H2AM13). The modified Ubiquitin gene was designed as a 76-amino acid fusion protein, expressed at the Nterminus of the nucleoprotein, as previously described (Rodriguez et al., 1997 (Rodriguez et al., , 2001 .
Three glycoprotein constructs were also generated based on the same viral isolate. Primary sequences for G N and G C glycoproteins were also submitted to TMpred software (Krogh et al., 2001 ) for prediction of transmembrane helices and to Phyre2 protein fold recognition server (Kelley and Sternberg, 2009 ) to grasp possible structural homology with available sequences of known structure. The first, G N -ecto, was designed based on the putative soluble ectodomain of glycoprotein N (amino acids 23e181 of the M-polyprotein). Similarly, the segments G C -ecto1 (aa: 678e947 of the Mpolyprotein) and G C -ecto2 (aa: 866e1323 of the M-polyprotein) were designed, cloned and expressed, as putatively soluble globular portions. Interestingly, the G C -ecto2 resulted to encompass the highly confident (96.2%) homology model (aa 953e1297) (Fig. 1A , inset) that Phyre2 returned in our recent sequences resubmission, as being similar to the severe fever with thrombocytopenia syndrome (SFTS) virus G C glycoprotein [PDB ID 5G47; (Halldorsson et al., 2016) ].
In all three glycoprotein constructs, an ATG codon was cloned to the 5'-end of the gene. For a negative control, an empty pOPING construct was used.
In vitro expression of DNA vaccine constructs
In order to verify the expression of all of the DNA vaccine candidates, each construct was transiently transfected in human embryonic kidney (HEK) 293T cells adapting protocols previously described (Aricescu et al., 2006) . Briefly, 1 mg of each construct was incubated with 2 mg of polyethylenimine (PEI) in a volume of 100 mL Dulbecco's Modified Essential Medium (DMEM) for 30 min, followed by incubation for 2 h in 10 6 cells in a total volume of 500 mL of DMEM. The cells were then supplemented with 2 mL of DMEM/10% FBS and incubated at 37 C for 24 h. Following transfection, the cells were washed with PBS, and lysed using 100 mL RIA buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM TriseCl pH 8.0). Western blotting of lysates was then performed using mouse anti-Histidine antibodies (GE Biosciences, USA) and HRP-conjugated anti-mouse IgG antibodies, and detected using enhanced chemiluminescence.
In the case of the pOPINE constructs, protein expression was also tested in bacteria, as this vector is a shuttle vector. For both N and Ub-N constructs, 100 ng of each plasmid was used to transform E. coli BL21 cells. Bacterial isolates were then cultured in 10 mL LBAmpicillin (100 mg/mL) and induced with IPTG for 20 h at 20 C. 10 mL of each culture was then run on 12% SDS PAGE, followed by Western blotting, and detection by enhanced chemiluminescence.
DNA immunization and SBV viral challenge
Six groups of IFNAR À/À mice were inoculated three times, intramuscularly, at two week intervals. Each group of mice (n ¼ 5) were vaccinated with each of the DNA vaccine constructs previously described (i.e. N, Ub-N, G N -ecto, G C -ecto1, G C -ecto2 and the negative control plasmids). One mouse in the N-group was found to be underweight prior to the experiment, and was not used for the subsequent challenge experiments. For all inoculations, the plasmids were purified using a GeneJet Maxiprep Endo-Free plasmid purification kit (Thermo Scientific, USA), and the purified plasmid was resuspended in sterile PBS at a concentration of 500 mg/mL, where 100 mL of plasmid was injected during each vaccination step (for a vaccination dose of 50 mg). Two weeks following the final DNA vaccination, all mice were challenged with subcutaneous injections of 10 8 TCID50 SBV (strain BH80/11-4), resuspended in 100 mL of DMEM. The changes in weights were analyzed for statistical significance using a one-way ANOVA test with Origin software (OriginLab, Northamton, MA).
Serological detection of SBV-specific IgG
Ten days following the third vaccination, blood samples were collected from each mouse, and serum was collected following coagulation. ELISA assay was performed on the plates coated with enriched SBV antigen. SBV antigen was obtained from collecting supernatant from BHK infected cells (MOI ¼ 0.01) after three days, and pelleted on a 20% sucrose cushion (in Tris-Buffered Saline pH 8.0). The sucrose cushion was then dialysed in TBS buffer pH 8.0. The antigenic extract (measured at TCID50 ¼ 10 8 /mL) was then diluted 1/1000 and 50 mL was added to each well of the ELISA plate.
The sera, previously inactivated at 56 C for 1 h, were added starting at a 1/100 dilution in PBS and serially diluted to 12800. The plates were incubated at 37 C for 1 h, followed by 3 washes with PBS/0.1%
Tween. 50 mL of HRP conjugated anti-mouse IgG (Sigma, USA) was then added to each well incubated for another hour at 37 C. Following three more washes with PBS/0.1% Tween, the plates were developed with 1-Step Ultra TMB substrate solution (Fisher Scientific, USA) for 30 min, stopped with 0.2 M sulfuric acid and measured at a wavelength of 450 nm. Statistical significance was determined using a one-way ANOVA test.
Detection and quantification of viremia by real-time RT-PCR
During the viral challenge described in Section 2.4, 100 mL of . Full-length nucleoprotein (N) was generated based on the SBV S-segment, while G N -ecto, G C -ecto1 and G C -ecto2 (indicated by the double-headed arrows) were generated based on the SBV M-segment; the inset represents the tridimensional homology model generated by Phyre2 as cartoon and colored dark blue to red from N-terminus to C-terminus. (B) Verification of in vitro expression of the DNA vaccine constructs. The ubiquitinated and nonubiquitinated N constructs (Ub-N and N, respectively) was transformed in BL21 E. coli, and expression was detected by 12% SDS-PAGE and western blotting using anti-histidine antibodies (left panel). All of the constructs were transfected in HEK293T cells (see Materials and Methods), and expression was detected by 12% SDS-PAGE and western blotting using anti-histidine antibodies. The putative protein bands are indicated by arrowheads. The theoretical molecular weights are indicated at the bottom of each lane. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
blood was collected from each mouse 3 and 6 dpi. RNA was extracted from 50 mL of each sample using the Paramagnetic Beads RNA Extraction Kit (Life River, Shanghai ZJ Biotech, China) according to the manufacturer's instructions, and eluted in 50 mL. The presence of SBV genomic RNA was detected by using the Monodose SBV dtec-RT-qPCR kit (Genetic PCR Solutions, Elche, Spain) using 5 mL of the extracted total RNA samples. Real-time RT-PCR was performed on an ABI7500 Real-time PCR system (Applied Biosystems, USA) using the FAM channel. The thermal profile used was as follows: 50 C for 10 min and 95 C for 60 s, followed by 40 cycles of the following: 95 C for 10 s and 60 C for 60 s.
Cell proliferation assay
A cell proliferation assay was performed from cells extracted from the spleens of mice following vaccination. A separate DNA vaccination experiment in IFNAR À/À mice was performed, but only for vaccination groups N, Ub-N, Gc-ecto1 and the negative control plasmids. Furthermore, the IFNAR À/À mice were only vaccinated twice. One week following the final vaccination, all mice were sacrificed, and splenocytes from individual mice were isolated in a manner similar to that previously described (Lorenzo et al., 2010) . Following isolation, a concentration of 10 6 splenocytes/ml from each mouse were stained with 5 mM of CellTrace CFSE cell proliferation reagent in DMSO, according to the manufacturer's instructions (Molecular Probes, USA). Next, cells were resuspended to a final concentration of 4 Â 10 6 cells/ml in RPMI 1640 medium supplemented with 10% foetal calf serum and seeded in 96 well plates pre-coated with 500 ng per well of anti-CD3e (BD-Biosciences) in triplicate in the presence of partially purified SBV extract (i.e. SBV antigen, prepared as described in Section 2.5).
Phytohemagglutinin (5 mg/ml) was used as a positive control, and medium without antigen was used as a negative control. Plates were incubated 3 days at 37 C in the presence of 5% CO 2 . After 72 h, cells were washed, stained for the surface markers PE-CD8a and APC-CD4 (BD Biosciences, USA), and fixed. Data were acquired by FACS analysis on a FACSscalibur (Becton Dickinson) and were analyzed with FlowJo (Tree Star 7.6.5 software). The fluorescence of CFSE staining was measured to determine the proportion of divided cells among CD8 þ cell subsets. The initial generation, and each of the following generations were used by the software to calculate the number of dividing cells.
Virus neutralization titration (VNT)
VNTs against the virus isolate used for challenge infection were performed as previously described (Wernike et al., 2013a) starting at a 1:10 dilution. All sera were tested in triplicates.
Results
Expression of DNA vaccine constructs in vitro
In order to verify the expression of all the cloned SBV genes prior to DNA vaccination studies, all of the constructs were transfected in HEK293 cells; and expression was detected by Western blotting against the C-terminal histidine tags. All genes encoding for the SBV proteins had specific bands corresponding to molecular weights that approximate their theoretical molecular weights (Fig. 1B) although, as expected, their degree of expression varied. In the case of N, a single, specific band corresponding to approximately 27 kDa was observed. However, the ubiquitinated nucleoprotein (Ub-N) also exhibited a comparably similar band, with a faint band corresponding to approximately 35 kDa, as indicated by the two arrowheads in the Ub-N lane. In order to confirm that Ub-N is initially expressed as a fusion protein, BL21 E. coli cells were transformed with both N and Ub-N, followed by induction with IPTG. Protein expression was then evaluated using western blotting. As seen in Fig. 1B left, both proteins were expressed at sizes corresponding to their theoretical values.
The construct encoding for the soluble N-terminal domain of glycoprotein N (G N -ecto) expressed a band of approximately 20 kDa, slightly higher than the theoretical molecular weight, possibly due to mammalian post-translational modifications (i.e. glycosylation). The constructs encoding for both segments of glycoprotein C (G C -ecto1 and G C -ecto2, respectively) were also found to express protein products slightly higher than their predicted molecular weights, migrating at approximately 37 (versus 31.3 kDa) and 58 kDa (versus 51.5 kDa), respectively.
These results demonstrated that candidate DNA vaccines for the individual SBV proteins are expressed in a mammalian cell system.
Generation of SBV-specific antibodies following vaccination
Ten days following the third vaccination with the SBV DNA constructs, serum was collected from the vaccinated mice, and SBVspecific IgG was measured using ELISA. As seen in Fig. 2A , both the Ub-N (yellow line) and N-(grey line) vaccinated mice exhibited the highest degree of SBV-specific antibodies.
Vaccinated IFNAR À/À mice display varying degrees of protection following SBV challenge
Following three vaccinations with the candidate DNA vaccine constructs the IFNAR À/À mice were subjected to viral challenge with virulent SBV, which was administered subcutaneously (see Materials and Methods). The clinical signs primarily associated with weight loss were measured for two weeks after virus challenge. The average change in weight is shown in Fig. 3A , where both the N and G C -ecto1 groups showed continued weight gain (relative to weights measured prior to viral challenge) throughout the entire experiment, with mice averaging 104% and 106% of pre-challenge weight. We also noted a qualitative difference between the overall appearance of these two groups, with mice in the N and G Cecto1 groups showing greater activity and appetite relative to the other groups. This was in contrast to the other vaccinated groups (i.e. Ub-N, G C -ecto2, G N -ecto and negative control), which exhibited continued weight loss until 7 dpi, followed by an eventual average weight gain between 7 and 15 dpi. It should be noted that in the case of G C -ecto1 and Ub-N, one mouse from each group had to be euthanized due to excessive morbidity. Aside from weight loss and overall physical activity, no other clinical signs were observed in the negative control mice. A detailed analysis of the weight changes of individual mice is shown in Fig. 3B , where the mean weights of all groups are shown until 7 dpi. While the masses of individual mice varied considerably, only N and G C -ecto1 had average body masses above 100% throughout the study.
These results demonstrate that only N and G C -ecto1 prevented weight loss following SBV challenge out of the six experimental groups used in this study.
Quantification of SBV viremia following challenge
Real-time RT-PCR was performed on mouse blood samples 3-and 6-dpi. As seen in Fig. 4 , all mice at all time points had viral loads of less than 6 Â 10 3 copies/mL at 3 dpi. While G C -ecto1 and N had the lowest viral loads at 3 dpi (2.0 Â 10 3 and 1.5 Â 10 3 copies/mL, respectively), all groups had average viral loads below 1.0 Â 10 4 . However, at 6 dpi, only G C -ecto1 and N had average viral loads of less than 1 Â 10 4 , with G C -ecto1 and N groups having average viral loads of 2.8 Â 10 3 and 1.7 Â 10 3 copies/mL, respectively. It should also be noted that in the G C -ecto1 group, 3 out of the 5 mice had no detectable viral loads. In the case of N, only one mouse had a nondetectable viral load. All other mice in all of the other groups had measurable levels of SBV viremia.
Virus neutralizing titers of vaccinated IFNAR À/À mice
Following the viral challenge experiments, the mode of immunity of the vaccine constructs was analyzed. In order to assess the extent of humoral immunity induced by the DNA vaccine candidates, VNTs were performed on mice that were vaccinated twice with either the N, Ub-N, G C -ecto1 or negative control constructs (see Materials and Methods). With dilutions starting at 1/10, none of the vaccinated groups had detectable levels of neutralizing titers (figure not shown).
Cell proliferation of isolated splenocytes vaccinated IFNAR
À/À mice For the T-cell assays, 4 groups of 5 IFNAR À/À mice were vaccinated twice using N, Ub-N, G C -ecto1 or the negative control plasmid. This vaccination strategy was a consequence of the fact that we found both N and G C -ecto1 were highly protective against virulent SBV challenge (neither of which involved the generation of neutralizing antibodies), thus we wanted to find out if cellmediated immunity could be induced with less DNA. One week following the second vaccination, the mice were sacrificed, and individual spleens were removed in order to measure the T-cell proliferative response. For each mouse, the degree of cellular proliferation was evaluated by measuring the degree of cell division by either CD4 þ or CD8 þ T-cells (as determined by flow cytometry -see Materials and Methods). The degree of cellular proliferation was indexed as the proportion of SBV antigen-stimulated cells that divided (as seen by decreased CFSE signals) relative to the proportion of cells that divided without SBV antigen. As seen in Fig. 5 , mice in the Gc-ecto1 group had the highest degree of cell proliferation, with a 45% increase in CD8 þ cellular proliferation, with a pvalue of less than 0.0001. The N-group also had a 6.5% increase in CD8 þ proliferation, with a p-value of 0.2, while the negative control group had approximately 1% proliferation. The Ub-N group had no statistically significant level of proliferation. When CD4 þ levels were analyzed, no significant differences in cellular proliferation were observed (data not shown).
Discussion
Evaluating the efficacy of DNA vaccines has multiple advantages. Firstly, the benefits of DNA vaccination over conventional inactivated/attenuated vaccine strains have been previously described (Babiuk et al., 2014; Kutzler and Weiner, 2008) . Briefly, lower cost of production, the lack of a required refrigeration/cold storage chain and the ability to store dehydrated DNA for prolonged periods of time enables for a cost-effective and practical method of vaccination. Furthermore, the use of DNA vaccine candidates encoding for different ORFs of the SBV genome enables for further immunological study of the virus; in particular, which components of the virus are responsible for protective immunity in the host. To date, little is known of the host immune response following SBV infection. While SBV virulence factors have been located to the G C (Varela et al., 2016) and NSs (Varela et al., 2013 (Varela et al., , 2016 components of the viral genome, there does not appear to be any data directly linking CD8
þ T-cell immunity following SBV infection. The use of IFNAR À/À mice as a model for SBV infection was previously found to display clinical signs that were far more pathogenic than SBV infection in ruminant animals (i.e. hemorrhagic fever, death), with the most common clinical sign being weight loss. . In this work, we aimed to validate five DNA vaccine candidates against SBV using a similarly aged IFNAR À/À model that differed only in the genetic background from previous studies (i.e. our Sv/ 129 mice model versus the C57BL/6 mice used elsewhere). To induce disease progression Sv/129 mice required higher viral titers, 10 8 TCID 50 , then the 10 3 or 10 4 TCID 50 used in C57BL/6 mice Kraatz et al., 2015) . Despite the difference in inoculum titers, the induction of weight loss at approximately 4 dpi was similarly observed, followed by recovery (i.e. weight gain) at 10 dpi in the surviving mice. Two promising targets have been identified on the basis that an effective DNA vaccine candidate should be able to prevent any significant weight loss, and limit viremia relative to unvaccinated mice. These DNA constructs, both capable to individually protect mice from SBV-induced weight loss, encode for two different components of the virus: (i) the segment aa 678e947 of the glycoprotein G C (G C -ecto1) and (ii) the full-length nucleoprotein. Furthermore, when the presence of the virus was measured, both constructs were found to significantly limit viremia at 3 and 6 dpi. Since SBV's discovery nearly five years ago, multiple vaccine candidates have been described and validated; these include inactivated vaccines (which are currently on the market), as well as recombinant NSm and NSs-deleted SBV strains (Kraatz et al., 2015) . However, until now, little was known about the ability of individual components of SBV in inducing a protective immune response. Thus G C -ecto1 and N could be used as individual DNA vaccines; and the possibility of using these targets in other forms of subunit vaccines can provide an alternative strategy in the development of antiviral measures against SBV. Furthermore, the availability of multiple vaccine targets would enable for validation of vaccines against heterologous challenge. This might be of particular interest when considering the hypervariable region associated with the Nterminus of G C . Previously, sequencing of two SBV genomes from two lambs within a single flock identified a 1200-nucleotide region of the M-segment that could undergo rapid variation within intraherd populations (Coupeau et al., 2013) . Interestingly, this region includes the segment of the protective G C -ecto1 DNA vaccine target, which has been described in this work. While this may suggest that the nucleoprotein, previously proven to be far more conserved (Fischer et al., 2013) would make for a more preferable construct for widespread vaccination programs, G C -ecto1 should still be considered. It should be noted that conflicting information pertaining to the G C 's hypervariable region (HVR) has been proposed when phylogenetic studies from a 2011-12 outbreak in cattle demonstrated a high degree of conservation of the HVR following SBV outbreaks (Coupeau et al., 2013) . Therefore, field studies using both vaccine candidates would be an important step in determining the extent of which target would be beneficial in preventing future SBV outbreaks.
Along with a DNA construct encoding for SBV nucleoprotein, an ubiquitinated fusion construct based on SBV N was also evaluated. Such a vaccine candidate was inspired by the detected increased antigenicity of RVFV nucleoprotein when a similar strategy was used (Boshra et al., 2011a) . Constructs encoding for ubiquitinated RVFV N showed near complete protection when challenged with RVFV in IFNAR À/À mice contrary to the limited protection offered by RVFV N (Boshra et al., 2011b) . In the case of SBV, the opposite effect was observed -N showed to be the most potent DNA vaccine construct in protecting against virulent SBV challenge, while its ubiquitinated counterpart appeared to increase pathogenicity following challenge (even relative to the negative control plasmid). Although both constructs generated high titers of SBV-specific antibodies, mice vaccinated with Ub-N showed the highest degree of weight loss, as well as the highest degree of viremia postinfection. These results appear to be corroborated when cellular immunity was analyzed. While G C -ecto1 and N had measurable levels of CD8 þ T-cell proliferation, the Ub-N group appeared to have a level of cellular proliferation comparable to the negative control group, suggesting an insignificant or deleterious effect of this construct on SBV-specific immunity. Furthermore, as no observable CD4 þ cellular proliferation was observed, these experiments indicate that SBV-mediated cellular immunity is primarily achieved through CD8 þ T-cell activation. Also, while G C -ecto1 and N had comparable levels of immune protection, N did not have a comparable level of cellular proliferation; and given that no vaccinated groups generated any neutralizing antibodies, one would have expected the nucleoprotein to have a greater level of cellular proliferation than observed. The fact that G C -ecto1 gave a significantly higher level of CD8 þ T cells activation may be attributed to (i) the lack of sufficient antigen presenting cells (APCs) from the isolated splenocytes; (ii) the lack of free cytosolic nucleoprotein (as would normally occur in an SBV-infected cells), or; (iii) the possibility of Viremia at 3 and 6 dpi was measured by extracting RNA from 50 mL of blood from each mouse, and the presence of SBV was quantified using real-time RT-PCR (see Materials and Methods). Results are presented as copy number/mL of blood, with the red-brick dash in each scatter plot denoting the mean. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) the existence of another nucleoprotein activated T-cell population that was not present in the spleen. Moreover, and contrary to other bunyaviruses such as RVFV where neutralizing antibody responses were observed following DNA vaccination regimes with a construct encoding for the M-segment glycoproteins (Lagerqvist et al., 2009; Lorenzo et al., 2010; Spik et al., 2006) , the SBV constructs used in this study failed to induce neutralizing antibodies (including those that provided protectively immunity following viral challenge). The IFNAR À/À mouse model used in this study demonstrates that SBV virulence occurs as early as 3 dpi, becoming most extensive at 6 dpi as observed by the significant weight loss and viremia in the negative control mice. Weight-loss and viremia were minimal in mice vaccinated with either G C -ecto1 or N, correlating with the increased levels of CD8 þ T-cell proliferation observed in vitro.
Considering that no neutralizing antibodies were observed, it appears as though both G C -ecto1 and N were able to induce protection entirely through cell-mediated immunity. This suggests that prior to viral challenge, both groups had stimulated, SBV-specific CD8 þ Tcells; and that following SBV challenge, both vaccinated groups were able to reduce virus replication within the first 3 days, thereby mitigating viremia and clinical signs. A further finding of our study was that the ubiquitin did not augment nucleoprotein-mediated immunity, an outcome seen also in other studies with DNA vaccines encoding for pseudorabies virus glycorproteins (Gravier et al., 2007) , as well as a tandemly fused BTT-cell epitope of foot-and-mouse disease virus (Borrego et al., 2006) . Contrarily, ubiquitin has been shown to increase protection against RVFV (Boshra et al., 2011b) , mycobacterial protein MPT64 (Wang et al., 2004) , porcine reproductive respiratory syndrome virus protein GP5 and lymphocytic chloriomeningitis virus nucleoprotein (Rodriguez et al., 1997) . Nevertheless, it is worth noting that such a contrast has never been observed within the same viral family (i.e. Bunyaviridae). While these results, along with the previous results from RVFV vaccination suggest that nucleoprotein-based vaccines may be promising candidates against bunyaviruses, the need to use immunostimulatory molecules/selfadjuvants is still an empirical strategy. Ultimately, nucleoproteintargeting could still be a promising vaccine strategy against other pathogenic bunyaviruses such as Crimean-Congo Hemorrhagic fever virus (CCHFV), Hantavirus, or severe fever with thrombocytopenia syndrome virus (SFTS).
In conclusion, we have shown that both SBV G C -ecto1 domain and nucleocapsid N protein represent viable candidates for DNA vaccination; and that these two constructs represent two individual targets for eliciting a protective immune response. Furthermore, the results obtained in these studies serve to offer new avenues for vaccine development and immune targeting in other bunyaviruses.
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